Recent publications published by researchers at the MRC WIMM.
Measure selection for an electronic patient-reported outcome (ePRO) system for CAR T-cell therapy patients: a modified Delphi consensus study
Hughes SE. et al, (2025), Eclinicalmedicine, 84
Multicentre adaptive randomised trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin versus calcineurin inhibitor-based or sirolimus-based post-transplant cyclophosphamide (Methods of T cell Depletion, MoTD trial).
Chakraverty R. et al, (2025), BMJ Open, 15
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies.
Khatsuria F. et al, (2024), Lancet Oncol, 25, e476 - e488
Integrating patient and public involvement and engagement in translational medicine.
Shaw KL. et al, (2024), Lancet, 404, 828 - 831
How Important Is Unrelated Donor Human Leukocyte Antigen Disparity in the Post-Transplant Cyclophosphamide Era?
Chakraverty R., (2024), J Clin Oncol
Predictive Performance of Cardiovascular Risk Scores in Cancer Survivors From the UK Biobank
McCracken C. et al, (2024), JACC: CardioOncology, 6, 575 - 588
The road to refractory graft-versus-host disease is paved with good intentions
North D. and Chakraverty R., (2024), Journal of Clinical Investigation, 134
Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity.
Cheminant M. et al, (2022), Blood
CAR-T Cells and Recent Advances in Clinical Cellular Immunotherapy
Gu Y. et al, (2022), Practical Transfusion Medicine: Sixth Edition, 543 - 553
Graft Versus Leukaemia (GvL): Identification & Characterisation of Alloreactive Antigens and Cognate T Cell Responses in Acute Myeloid Leukemia
Sweeney C. et al, (2022), BLOOD, 140, 1576 - 1578
Allogeneic HSCT For Adolescents and Adults With Inborn Errors of Immunity: A Retrospective Study of The Inborn Errors Working Party (IEWP)
Albert M. et al, (2021), BONE MARROW TRANSPLANTATION, 56, 101 - 102
Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party (Bone Marrow Transplantation, (2021), 56, 3, (605-613), 10.1038/s41409-020-01069-w)
Schetelig J. et al, (2021), Bone Marrow Transplantation
Phenotype Reversal, Excellent Overall, GVHD-free And Graft Failure-Free Survival In 55 Adolescents And Adults With Inborn Errors of Immunity Following Reduced Intensity Allogeneic HSCT
Fox TA. et al, (2021), BONE MARROW TRANSPLANTATION, 56, 103 - 105
Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function.
Cuadrado MM. et al, (2020), Haematologica, 105, 2639 - 2646
Very Long-Term Follow Up of 83 Adults WHO Underwent Allogeneic HSCT in Childhood for Primary Immunodeficiency (PID): A Single Centre Experience
Day J. et al, (2020), BONE MARROW TRANSPLANTATION, 55, 106 - 106
CMV-Specific T-Cell Therapy Improves Immune Reconstitution Following Unrelated Donor HSCT: Results of a Randomized Controlled Trial
Chen F. et al, (2014), BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20, S49 - S49